Posted by iladvocate on September 21, 2008, at 15:54:40
In reply to Re: Glycine as Antipsychotic - JEREON !!!!!, posted by mike1975 on September 21, 2008, at 15:29:14
> hi everyone,
>
> It seems that the latest study found glycine ineffective:
>
> The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
>
> Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT.
>
> Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA.
>
> OBJECTIVE: Patients with schizophrenia frequently present with negative symptoms and cognitive impairments for which no effective treatments are known. Agents that act at the glycine site of the N-methyl-D-aspartic acid (NMDA) glutamatergic receptor have been suggested as promising treatments for moderate to severe negative symptoms and cognitive impairments. METHOD: The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST) was a 16-week double-blind, double-dummy, parallel group, randomized clinical trial of adjunctive glycine, D-cycloserine, or placebo conducted at four sites in the United States and one site in Israel. The participants were 157 inpatients and outpatients who met DSM-IV criteria for schizophrenia or schizoaffective disorder and retrospective and prospective criteria for moderate to severe negative symptoms without marked positive, depressive, or extrapyramidal symptoms. The primary outcome measures were the average "rate of change" of Scale for the Assessment of Negative Symptoms (SANS) total scores and change in the average cognitive domain z scores. RESULTS: There were no significant differences in change in the SANS total score between glycine and placebo subjects or D-cycloserine and placebo subjects. A prespecified test for the site-by-treatment-by-time interaction was significant in post hoc tests. One site had greater reduction in the SANS total score for patients receiving D-cycloserine relative to patients receiving placebo. A second site had greater reduction in the SANS total score for placebo patients compared with glycine patients. There were no significant differences between glycine and placebo or D-cycloserine and placebo subjects on the average cognition z score. CONCLUSIONS: The study results suggest that neither glycine nor D-cycloserine is a generally effective therapeutic option for treating negative symptoms or cognitive impairments.
>
> Any thoughts?
>
> Take care
>
> Mike
>Many of the double blind placebo studies have found inadaquete results for many medications. It should be noted also that glycine is just a compound and that there are other anti-psychotics in study that are glutamate antagonists that work in a more specific manner. Additionally, the study gave the glycine at one large dose whereas in myself it is short acting and needs to be titrating throughout the day. My psychopharmocologist will be publishing the results of my use of glycine as a primary antipsychotic. I testified last week at the psychiatric hospital that first developed Clozaril. My psychopharmocologist confirmed to the director of psychiatry there that my recovery with glycine was "as good as all approved FDA anti-psychotics or better". Obviously, one person's recovery does not confirm everyone's but it shows that although for some people it may be ineffective that for myself as identified through the same standards as used in the study I have made a full recovery and that other people might as well. They just need to keep researching more anti-psychotics in this class and other study classes of anti-psychotics as well. Every anti-psychotic currently available except for Clozaril (which has its own set of hazards) will eventually cause people to develop tardive dyskinesia (5% per person per year with the typicals, 2.5% per person per year with the atypicals) plus the ever present risk of diabetes. As well the tardive conditions are worse than they had originally let the public know such as tardive psychosis which I am in study for and am being treated with Zofran. This information was confirmed with my psychopharmocologist who let me publicize this but I cannot print his name and he works under standard clinical practice. Its too important to let these studies fall apart for other people's recovery.
poster:iladvocate
thread:850659
URL: http://www.dr-bob.org/babble/20080915/msgs/853265.html